BlackRock
KLRS

BlackRock’s Kalaris Therapeutics KLRS Stock Holding History

BlackRock’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
54,442
+18,399
+51% +$95.6K ﹤0.01% 4788
2026
Q1 		$208K Sell
36,043
-2,411
-6% -$21.4K ﹤0.01% 4756
2025
Q4 		$325K Sell
38,454
-1,925
-5% -$12.3K ﹤0.01% 4601
2025
Q3 		$233K Buy
40,379
+2,223
+6% +$7.35K ﹤0.01% 4648
2025
Q2 		$102K Buy
38,156
+10,642
+39% +$48K ﹤0.01% 4835
2025
Q1 		$221K Sell
27,514
-3
-0% -$29 ﹤0.01% 4582
2024
Q4 		$266K Hold
27,517
– – ﹤0.01% 4565
2024
Q3 		$512K Sell
27,517
-49
-0.2% -$857 ﹤0.01% 4318
2024
Q2 		$459K Sell
27,566
-119,644
-81% -$2.11M ﹤0.01% 4368
2024
Q1 		$2.56M Sell
147,210
-6,099
-4% -$99.5K ﹤0.01% 3913
2023
Q4 		$2.4M Sell
153,309
-13,892
-8% -$548K ﹤0.01% 3970
2023
Q3 		$8.27M Buy
167,201
+22,664
+16% +$1.54M ﹤0.01% 3446
2023
Q2 		$11.3M Buy
144,537
+28,299
+24% +$2.69M ﹤0.01% 3364
2023
Q1 		$10.5M Sell
116,238
-6,231
-5% -$794K ﹤0.01% 3293
2022
Q4 		$14.5M Buy
122,469
+6,492
+6% +$1.1M ﹤0.01% 3200
2022
Q3 		$21M Buy
115,977
+8,212
+8% +$1.28M ﹤0.01% 3005
2022
Q2 		$9.67M Buy
107,765
+10,769
+11% +$1.13M ﹤0.01% 3521
2022
Q1 		$15.1M Buy
96,996
+2,728
+3% +$544K ﹤0.01% 3351
2021
Q4 		$28.1M Buy
94,268
+15,434
+20% +$7.16M ﹤0.01% 3058
2021
Q3 		$45.4M Buy
78,834
+2,856
+4% +$1.32M ﹤0.01% 2723
2021
Q2 		$34.5M Sell
75,978
-27,199
-26% -$14M ﹤0.01% 2945
2021
Q1 		$55.5M Buy
103,177
+24,284
+31% +$20.4M ﹤0.01% 2547
2020
Q4 		$69.8M Buy
78,893
+27,955
+55% +$21.5M ﹤0.01% 2276
2020
Q3 		$32.2M Buy
+50,938
New +$34.8M ﹤0.01% 2562

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's KLRS Position: Q2 2026 in Review

BlackRock increased its Kalaris Therapeutics (KLRS) stake by 51% in Q2 2026, buying an estimated $95.6K and bringing the position to 54,442 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #4788.

BlackRock first reported a position in KLRS in Q3 2020 and has held it in 24 quarters since. The position peaked at $69.8M in Q4 2020. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • BlackRock held 54,442 shares of Kalaris Therapeutics worth $222K as of Q2 2026.
  • BlackRock bought 18,399 Kalaris Therapeutics shares in Q2 2026, an estimated $95.6K.
  • Kalaris Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4788 holding.
  • BlackRock first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • BlackRock's Kalaris Therapeutics position peaked at $69.8M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.